Literature DB >> 12021633

Simple method based on fluorescent detection for the determination of 4-hydroxycyclophosphamide in plasma.

Laimonas Griskevicius1, Lennart Meurling, Moustapha Hassan.   

Abstract

Cyclophosphamide is a prodrug used both as a single drug and in combination chemotherapy. Cyclophosphamide is converted to its active metabolite (4-hydroxycyclophosphamide) by the cytochrome P450 enzymes. A liquid chromatography method including liquid-liquid extraction and protein precipitation in one step was developed to measure 4-hydroxycyclophosphamide in plasma. The 4-hydroxycyclophosphamide was stabilized and converted to a fluorescent dansylhydrazone derivative, which was chromatographed on a reverse-phase column and detected using a spectrofluorometric detector at excitation of 350 nm and emission of 550 nm. The limit of quantitation was 60 ng/mL and the between-day accuracy and precision were less than 9%. The method was applied to the analysis of plasma from patients who had received an intravenous infusion of 1 g/m(2) cyclophosphamide.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021633     DOI: 10.1097/00007691-200206000-00013

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  4 in total

1.  Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.

Authors:  Laimonas Griskevicius; Umit Yasar; Mia Sandberg; Mats Hidestrand; Erik Eliasson; Gunnel Tybring; Moustapha Hassan; Marja-Liisa Dahl
Journal:  Eur J Clin Pharmacol       Date:  2003-04-09       Impact factor: 2.953

2.  The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.

Authors:  Nuala A Helsby; Chung-Yee Hui; Michael A Goldthorpe; Janet K Coller; May Ching Soh; Peter J Gow; Janak Z De Zoysa; Malcolm D Tingle
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

3.  Cytochrome P450 2J2, a new key enzyme in cyclophosphamide bioactivation and a potential biomarker for hematological malignancies.

Authors:  I El-Serafi; M Fares; M Abedi-Valugerdi; P Afsharian; A Moshfegh; Y Terelius; Z Potácová; M Hassan
Journal:  Pharmacogenomics J       Date:  2015-01-20       Impact factor: 3.550

4.  Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation.

Authors:  Ibrahim El-Serafi; Parvaneh Afsharian; Ali Moshfegh; Moustapha Hassan; Ylva Terelius
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.